Nebenwirkungen · Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka)
Lenalidomide Krka d.d. Novo mesto 2.5 mg hard capsules Lenalidomide Krka d.d. Novo mesto 5 mg hard capsules Lenalidomide Krka d.d. Novo mesto 7.5 mg hard capsules Lenalidomide Krka d.d. Novo mesto 10 mg hard capsules Lenalidomide Krka d.d. Novo mesto 15 mg hard capsules Lenalidomide Krka d.d. Novo mesto 20 mg hard capsules Lenalidomide Krka d.d. Novo mesto 25 mg hard capsules · Abschnitt 4.8 · PDF-Seite 31
HOS-148825 · Präparat HOS-099972
Newly diagnosed multiple myeloma: patients who have undergone ASCT treated with lenalidomide maintenance Lenalidomide maintenance after ASCT is associated with a higher frequency of Grade 4 neutropenia compared to placebo maintenance (32.1% vs 26.7% [16.1% vs 1.8% after the start of maintenance treatment] in CALGB 100104 and 16.4% vs 0.7% in IFM 2005-02, respectively). Treatment-emergent AEs of neutropenia leading to lenalidomide discontinuation were reported in 2.2% of patients in CALGB 100104 and 2.4% of patients in IFM 2005-02, respectively. Grade 4 febrile neutropenia was reported at similar frequencies in the lenalidomide maintenance arms compared to placebo maintenance arms in both studies (0.4% vs 0.5% [0.4% vs 0.5% after the start of maintenance treatment] in CALGB 100104 and 0.3% vs 0% in IFM 2005-02, respectively).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2021-12-17T12:56:00Z · SHA-256 9b15721a878f6b48caf8691524d0cc634862d39053d4ce108521191ff1511e31 · Passage 47c9a872ea2e331e08108f4c5a779a4edb40b450632f43f1724c54e8cfd59a2f · Zeichen 36255–37091 im Abschnitt